<DOC>
	<DOCNO>NCT00353691</DOCNO>
	<brief_summary>To compare change glycemic control baseline endpoint ( last available posttreatment assessment ) measure HbA1c pediatric subject type 2 diabetes receive either glimepiride metformin monotherapy .</brief_summary>
	<brief_title>Glimepiride v Metformin Monotherapy Pediatric Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Subjects type 2 diabetes treat diet exercise least 2 week prior randomization , previously currently treat oral agent respond diet , exercise , oral therapy least 3 month ( document HbA1c &gt; 7.5 % ) . 2 . Subjects complete glimepiride pharmacokinetic Study HOE 490/4045 preselected site within 3 week prior screen period also permit enroll . 3 . Subjects require negative islet cell antigen ( ICA ) glutamic acid decarboxylase ( GAD ) autoantibodies Cpeptide level 90 minute â‰¥ 1.5 ng/mL . The HbA1c require &gt; 7.1 % screen &lt; 12.0 % day randomization . EXCLUSION CRITERIA : Subjects meet follow criterion include study : 1 . A history acute metabolic complication diabetic ketoacidosis within 3 month screen 2 . On insulin therapy , receive insulin &gt; 6 week , 3 month prior randomization 3 . On weightreduction medication 4 . Known hypersensitivity biguanides , sulfonamide , insulin 5 . Pregnant lactating female 6 . Clinically significant renal ( serum creatinine level &gt; 1.0 mg/dL ) hepatic disease ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 2.5 time upper limit normal [ ULN ] ) 7 . GI disorder may interfere absorption study drug 8 . Chronic use medication know affect glucose level intermittent use systemic corticosteroid large dose inhaled steroid 9 . Clinically significant laboratory abnormality screen laboratory test medical condition opinion investigator would affect outcome study 10 . History drug alcohol abuse 11 . Treatment investigational product last 3 month study entry 12 . History noncompliance regard followup medical care 13 . Any disease condition opinion investigator and/or sponsor may interfere completion study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>